Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Cerebral Edema ll: Pathophysiology01:22

Cerebral Edema ll: Pathophysiology

Vasogenic edema is a major form of cerebral edema characterized by abnormal accumulation of fluid in the brain’s extracellular space due to disruption of the blood–brain barrier (BBB). The BBB is a specialized structure composed of endothelial cells connected by tight junctions, supported by astrocytic endfeet and a basement membrane. Under normal conditions, it tightly regulates the movement of ions, proteins, and solutes between the bloodstream and brain parenchyma. When this barrier loses...
Transient Ischemic Attack l: Introduction01:26

Transient Ischemic Attack l: Introduction

A transient ischemic attack (TIA) is a brief episode of neurological dysfunction caused by a temporary, focal reduction in cerebral blood flow. Although symptoms resemble those of an ischemic stroke, the interruption in perfusion is short-lived and does not cause permanent infarction. TIAs are clinically important because they often serve as early warning events for future stroke.Mechanisms of Transient Cerebral IschemiaTransient cerebral ischemia may arise through several mechanisms. One...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genomic characterization of ceftazidime/avibactam-resistant KPC-producing <i>Klebsiella pneumoniae</i> in bloodstream infections indicates OmpK35 and OmpK36 as pivotal key players in resistance mechanisms.

Frontiers in microbiology·2026
Same author

Social and Behavioral Correlates of Self-Perceived Psychological Distress in Celiac Disease During the COVID-19 Pandemic: An Exploratory Cross-Sectional Study (COVIMPACT).

Nutrients·2026
Same author

Dance/movement therapy in psychotic disorders and eating disorders: a systematic review.

Frontiers in psychiatry·2026
Same author

Preclinical Evidence for Antidepressant-like Effects of Histamine H3 Receptor Modulation: A Systematic Review and Meta-Analysis.

Life (Basel, Switzerland)·2026
Same author

Genomic characterization of ceftazidime/avibactam-resistant <i>Klebsiella pneumoniae</i>: a retrospective analysis on clinical isolates from an Italian transplant unit.

Frontiers in microbiology·2026
Same author

Association between unrecognized donor bloodstream infection and outcomes in solid organ transplant recipients: a prospective observational cohort study.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2026
Same journal

Clinical response after cerebrospinal fluid shunting in complex versus pure idiopathic normal pressure hydrocephalus: A systematic review and meta-analysis.

Clinical neurology and neurosurgery·2026
Same journal

Preoperative sleep medication use and outcomes following lumbar spine surgery.

Clinical neurology and neurosurgery·2026
Same journal

Long-term real-world outcomes and device management of intrathecal drug delivery systems: A 16-year single-center experience with a primary focus on baclofen therapy.

Clinical neurology and neurosurgery·2026
Same journal

Trends and safety of outpatient versus inpatient lumbar interbody fusion - A national cohort study.

Clinical neurology and neurosurgery·2026
Same journal

A case report on αIN antibody-mediated paraneoplastic cerebellar ataxia.

Clinical neurology and neurosurgery·2026
Same journal

Early prediction of prolonged mechanical ventilation in invasively ventilated patients with subarachnoid hemorrhage: A MIMIC-IV prediction model study.

Clinical neurology and neurosurgery·2026
See all related articles

Related Experiment Video

Updated: May 29, 2026

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
04:22

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Published on: May 30, 2025

Vasogenic erectile dysfunction Topiramate-induced.

Carlo Civardi1, Alessandra Collini, Paolo Gontero

  • 1Department of Neurology, Università del Piemonte Orientale A. Avogadro, Novara, Italy. c civardi@yahoo.com

Clinical Neurology and Neurosurgery
|August 27, 2011
PubMed
Summary
This summary is machine-generated.

Topiramate, an antiepileptic drug, can cause reversible erectile dysfunction. This study found the dysfunction is not linked to reproductive hormone changes, suggesting a vasogenic cause for Topiramate-induced erectile issues.

Related Experiment Videos

Last Updated: May 29, 2026

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
04:22

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Published on: May 30, 2025

Area of Science:

  • Neurology
  • Endocrinology
  • Pharmacology

Background:

  • Topiramate is an antiepileptic medication with known side effects.
  • Erectile dysfunction has been anecdotally linked to Topiramate use.
  • The underlying mechanism for this side effect requires elucidation.

Observation:

  • Two male patients on Topiramate treatment developed reversible erectile dysfunction.
  • Serum levels of total, free, and bioavailable testosterone were monitored.
  • Sex hormone-binding globulin levels were also assessed during and after treatment.

Findings:

  • Topiramate treatment did not significantly alter reproductive hormone levels in the observed patients.
  • No correlation was found between Topiramate use and changes in testosterone or sex hormone-binding globulin.
  • The erectile dysfunction experienced by patients was not attributable to hormonal imbalances.

Implications:

  • The mechanism of Topiramate-induced erectile dysfunction may involve vasogenic factors rather than hormonal disruption.
  • Further research into vascular mechanisms is warranted to understand and manage this side effect.
  • This finding could inform clinical practice regarding Topiramate prescriptions and patient counseling.